Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer
The heir to the Roche pharmaceuticals dynasty on how corporate power can be harnessed in the quest for sustainability
High rates of vomiting among those who took strong doses in trials have unsettled investors
The first in an FT series looking at the new energy behind the fight for cancer cures
The Swiss company had the first option on a drug that could now become a leading anti-obesity treatment
Swiss drugmaker examines options for Flatiron Health after acquisition has disappointed
Swiss drugmaker unveils promising data for obesity drug
Weekly injection delivered 18.8% weight loss over 24 weeks
Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
Potential remedy targets leading antibiotic-resistant pathogen that causes life-threatening infections in patients
The Swiss pharma group needs to settle investor jitters with its latest acquisition
Swiss pharmaceutical group is under pressure to strengthen its pipeline of medicines
Bolt-on acquisitions, however interesting, will not get Swiss pharmaceuticals group Roche out of its funk
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
Shares in Swiss pharma group rally after analyst discovers data on immunotherapy medicine on website
BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances
Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease
Swiss pharma group says demand for coronavirus tests dropped as severity of virus ebbed
Severin Schwan will be succeeded by Thomas Schinecker, head of drugmaker’s diagnostics unit
Do not dismiss the possibility of another upturn in the coronavirus testing market
Swiss pharmaceuticals group expects revenue from coronavirus treatments will decline this year
New therapies replace a blunderbuss with a stiletto
Twenty-year shareholding had kept the two Swiss drugmakers closely linked
Plus, inside the cut-throat game of private equity and European football
